Ofatumumab for post-transplant lymphoproliferative disorder | Zendy

Madhav Seshadri | Zendy; Genevieve M. Crane | Zendy; Usama Gergis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ofatumumab for post-transplant lymphoproliferative disorder

Author(s) -

Madhav Seshadri,

Genevieve M. Crane,

Usama Gergis

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.04.004

Subject(s) - post transplant lymphoproliferative disorder , ofatumumab , medicine , rituximab , lymphoma

Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research